Suzhou Fushilai Pharmaceutical301258.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Suzhou Fushilai Pharmaceutical (301258.SZ) trades at a P/E of 356.00x, P/B of 1.29x, P/S of 6.33x, and a dividend yield of 0.83%.
Longitudinal percentile comparison: P/E sits at the 96th percentile over the trailing 10Y window (vs. 94th percentile over 3Y); P/B sits at the 26th percentile over the trailing 10Y window (vs. 39th percentile over 3Y); P/S sits at the 49th percentile over the trailing 10Y window (vs. 56th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 96th percentile within its industry and the 96th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.17%, ranking at the 95th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 69.5 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 0.83% comes from cash dividends, with an implied ~3.34% from buybacks — a fairly balanced mix of both channels. Suzhou Fushilai Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 301258 · SZSE: 301258 · 301258
Want the full picture on whether Suzhou Fushilai Pharmaceutical (301258.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 356.00 | ||||||
| P/B (MRQ) | 1.29 | ||||||
| P/S (TTM) | 6.33 | ||||||
| Dividend Yield | 0.83% | ||||||
| Buyback + Div Yield | 4.17% |